- New Gene Therapy, Type 1/Type 4 Research Projects Approved
The CMTA today announced another $335,000 in grants to top CMT scientists leading the field in CMT Type 1 research. The grants cover work on types 1A, 1B and 1X and other demyelinating forms of CMT, including type 4.Read more ... - New Gene Therapy Development Program for CMT2A
Passage Bio, a genetic medicines company developing AAV-delivered gene therapies, today announced a gene therapy development program for Charcot-Marie-Tooth Neuropathy Type 2A (CMT2A).Read more ... - $1 Million Gift Pledged to CMT Type 2 Research!
Bob and Gail Buuck are big believers in “impact giving,” They have pledged a $1 million gift to advance CMT Type 2 research.Read more ... - Cycle (and Walk!) for TWICE the impact!
When you participate in the Cycle 4 CMT in Vermont or do your “OWN” challenge, your donation will be doubled thanks to an exciting dollar-for-dollar match!Read more ... - 2019 Summer CMTA Report
All in the Family: The many branches of the CMTA family tree—the patients, the families that support them and the doctors who treat them.Read more ...
When you participate in the Walk 4 CMT campaign, you fund patient programs and treatment research initiatives to better the lives of the the 2.8 million people living with CMT.
In honor of CMTA Board Member Steve O'Donnell's quest for a CMT cure, the Plane Apparel Company will donate $5 from the purchase of each CMT Survivor Tee to the CMTA.